JP2009518293A5 - - Google Patents

Download PDF

Info

Publication number
JP2009518293A5
JP2009518293A5 JP2008543435A JP2008543435A JP2009518293A5 JP 2009518293 A5 JP2009518293 A5 JP 2009518293A5 JP 2008543435 A JP2008543435 A JP 2008543435A JP 2008543435 A JP2008543435 A JP 2008543435A JP 2009518293 A5 JP2009518293 A5 JP 2009518293A5
Authority
JP
Japan
Prior art keywords
composition
pirfenidone
administration
medicament
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543435A
Other languages
English (en)
Japanese (ja)
Other versions
JP5175740B2 (ja
JP2009518293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045750 external-priority patent/WO2007064738A1/en
Publication of JP2009518293A publication Critical patent/JP2009518293A/ja
Publication of JP2009518293A5 publication Critical patent/JP2009518293A5/ja
Application granted granted Critical
Publication of JP5175740B2 publication Critical patent/JP5175740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543435A 2005-12-02 2006-11-29 ピルフェニドン療法に付随する有害事象を低減する方法 Active JP5175740B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
US60/741,976 2005-12-02
PCT/US2006/045750 WO2007064738A1 (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012187515A Division JP2012229275A (ja) 2005-12-02 2012-08-28 ピルフェニドン療法に付随する有害事象を低減する方法

Publications (3)

Publication Number Publication Date
JP2009518293A JP2009518293A (ja) 2009-05-07
JP2009518293A5 true JP2009518293A5 (enExample) 2009-12-17
JP5175740B2 JP5175740B2 (ja) 2013-04-03

Family

ID=37807840

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008543435A Active JP5175740B2 (ja) 2005-12-02 2006-11-29 ピルフェニドン療法に付随する有害事象を低減する方法
JP2012187515A Withdrawn JP2012229275A (ja) 2005-12-02 2012-08-28 ピルフェニドン療法に付随する有害事象を低減する方法
JP2015002231A Pending JP2015061888A (ja) 2005-12-02 2015-01-08 ピルフェニドン療法に付随する有害事象を低減する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012187515A Withdrawn JP2012229275A (ja) 2005-12-02 2012-08-28 ピルフェニドン療法に付随する有害事象を低減する方法
JP2015002231A Pending JP2015061888A (ja) 2005-12-02 2015-01-08 ピルフェニドン療法に付随する有害事象を低減する方法

Country Status (13)

Country Link
US (1) US20070203202A1 (enExample)
EP (2) EP2316453B1 (enExample)
JP (3) JP5175740B2 (enExample)
AT (1) ATE497766T1 (enExample)
CA (1) CA2631646C (enExample)
CY (1) CY1111355T1 (enExample)
DE (1) DE602006020070D1 (enExample)
DK (1) DK1965797T3 (enExample)
ES (2) ES2565190T3 (enExample)
PL (1) PL1965797T3 (enExample)
PT (1) PT1965797E (enExample)
SI (1) SI1965797T1 (enExample)
WO (1) WO2007064738A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
MX2009006526A (es) * 2006-12-18 2009-06-30 Intermune Inc Metodo para suministrar terapia con pirfenidona a un paciente.
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
KR101767849B1 (ko) 2007-06-20 2017-08-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
AU2012225611B2 (en) * 2011-03-08 2016-09-15 Auspex Pharmaceuticals, Inc. Substituted N-Aryl pyridinones
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2846824C (en) * 2011-09-14 2021-03-16 Shionogi & Co., Ltd. Pharmaceutical composition for inhalation
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
HK1220133A1 (zh) 2013-03-15 2017-04-28 Intermune, Inc. 改善微血管完整性的方法
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2004110245A2 (en) * 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Similar Documents

Publication Publication Date Title
JP2009518293A5 (enExample)
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
JP7025319B2 (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2015518897A (ja) 過体重および肥満を治療する方法
JP2005513107A5 (enExample)
JP2013544290A5 (enExample)
TW200524639A (en) Memantine oral dosage forms
TW201306825A (zh) 狀況治療之改良套裝
CN110475547A (zh) 治疗多发性硬化症的组合物和方法
Prenner et al. Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blinded, placebo-controlled study
EP2034829A1 (en) Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association
American Dental Association ADA dental drug handbook: a quick reference
CN106474095A (zh) 一种用于治疗口腔真菌的口腔粘膜粘贴剂及其制备方法
JP4318899B2 (ja) 抗感冒剤
CN103006657B (zh) 一种含有愈创木酚的复方化学药物
De Ruiter et al. Trifarotene (Aklief, Galderma)
Bharath Pharmaceutics: Formulations and dispensing pharmacy
Loh et al. Adrenaline autoinjectors-what pharmacists need to know
CN103191170A (zh) 一种辅助治疗2型糖尿病的保健品及其制备方法
Wellbery Smoking Ban Has Health Benefits for Bar Workers
JP2008505137A5 (enExample)
Washington et al. A Deceptive Urethral Discharge
CN106389544A (zh) 神志康复组合物
BRMU8701824U2 (pt) embalagem, ou kit de medicamentos, ou apresentaÇço facilitadora da administraÇço de medicamentos por parte dos pacientes